No pneumococcal vaccine? Join Dr. Tytus in Hamilton!

Consider Participating in a Clinical Research Study

Dr. Richard Tytus is testing an investigational study
vaccine to see if it can help protect against
pneumococcal disease. Your participation in this study can help advance research to prevent serious illness.

Approved by Research Ethics Board. No obligation.

Meet Richard Tytus, Family Doctor & Founder of Hamilton Medical Research Group

My vision: A community in which everyone is able to achieve their optimal level of health and wellness by enabling the introduction and innovation of new treatments and therapies.
Dr. Richard Tytus practised as a GP anesthetist for five years in Blind River, Ontario, before practising in downtown Hamilton. He is an associate clinical professor in the Department of Family Medicine at McMaster University. Dr. Tytus served as president of the Hamilton Academy of Medicine and is currently a director of the Ontario Medical Association (OMA) Board (District 4).
Dr. Tytus has received numerous awards, including the 2012 Family Physician of the Year presented by the Ontario College of Family Physicians.
Are you eligible to participate?

Take a more active role in your health care today.

Dr. Richard Tytus is looking at a potential new oral drug for adults with COVID-19 who are at risk for serious disease.
Hamilton Medical Research Group
700 Main Street East
Hamilton, Ontario  L8M 1K7

© Copyright 2023, All Rights Reserved by Banty (our partner in clinical trial recruitment)

Study Summary

This study is evaluating the safety, tolerability, and immunogenicity of an investigational vaccine in adults age 18-64 who have never received a pneumococcal vaccine (except for childhood vaccination prior to the age of five). Read more about the study and check your eligibility below.

Being in the study is voluntary. Even if you decide to join and then change your mind, you can stop participating at any time.

Pneumococcal disease is an illness caused by certain germs (bacteria), called Streptococcus pneumoniae. These germs can cause serious infections in the ears, nose, lungs, blood, or brain.

Some people have a higher risk of getting pneumococcal disease. This includes people with conditions such as diabetes, heart disease, kidney disease, liver disease, and lung disease.

Vaccines help the body fight infections due to diseases like pneumococcal disease, and may help prevent serious illness. New vaccines must be tested to show that they work.

You may be able to take part in this study if you are 18-64 years of age and have not previously received a pneumococcal vaccine or haven’t had one since childhood, are at an increase risk of getting pneumococcal disease, and have not had a positive test for it within the last 3 years. There are additional requirements which the study doctor can discuss with you.

Your participation in the study will last about 6 months, and you will visit the study center 4 or 5 times. You will also have 3 telephone call visits with the study staff.

Tests and exams during this study include your medical history, body temperature, blood samples, a physical exam, and keeping a diary at home of your temperature and any side effects. Additional tests to determine the status of your increased-risk condition may be required.

The study vaccines and study-related tests will be provided at no cost. You may also be reimbursed for study travel and related expenses.

The study is testing an investigational study vaccine to see if it can help protect against pneumococcal disease. This trial will compare the investigational study vaccine to PCV15 (pneumococcal 15-valent conjugate vaccine), and PPSV23 (pneumococcal 23-valent conjugate vaccine). PCV15 and PPSV23 are approved pneumococcal vaccines in some countries but may not be approved in your country.

This study will evaluate the safety and tolerability of the investigational study vaccine, how the body responds to it and how it protects compared to receiving PCV15 and PPSV23. The study is for adults who are at an increased risk of getting pneumococcal disease.

Eligibility Checker